Acrivon Therapeutics, Inc. — Q3 2023 Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023. The filing was signed November 9, 2023. Acrivon is a clinical-stage oncology company developing medicines and patient-selection tests using its AP3 proteomics platform. Its lead candidate, ACR-368, is in a Phase 2 trial; ACR-2316 and other programs are preclinical. The company reported no product revenue.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $10.3m | $7.9m | $30.5m | $18.1m |
| General and administrative expense | $5.9m | $1.6m | $15.5m | $4.6m |
| Total operating expenses | $16.1m | $9.6m | $46.1m | $22.7m |
| Net loss | $14.5m | $9.2m | $41.1m | $22.2m |
| Other income, net | $1.7m | $0.4m | $4.9m | $0.5m |
| Net loss per share, basic and diluted | $0.66 | $5.17 | $1.87 | $12.55 |
At September 30, 2023, cash and cash equivalents were $29.9m and short-term investments were $112.2m, totaling $142.1m in cash, cash equivalents and investments. Total assets were $151.1m; current liabilities were $9.3m; and stockholders’ equity was $138.1m. Accumulated deficit was $97.2m. The filing reports no borrowings; operating lease liabilities totaled $4.4m. Profitability and operating margins are not meaningful because the company has no revenue.
Net cash used in operating activities was $30.3m for the nine months, versus $20.8m in 2022. Investing activities provided $30.2m, mainly reflecting $70.3m of investment maturities offset by $39.9m of investment purchases. Financing activities provided $0.5m, primarily from option exercises. Cash, cash equivalents and restricted cash increased $0.4m to $30.3m.
Changes versus the prior comparable periods
- Q3 net loss increased $5.3m year over year; nine-month net loss increased $18.9m. Nine-month operating expenses more than doubled, rising $23.3m.
- Nine-month R&D expense rose $12.5m, including increased ACR-368 trial costs, personnel expense and preclinical development activity, including ACR-2316.
- Nine-month G&A expense rose $10.9m, driven largely by employee-related costs—including stock-based compensation—and higher public-company professional fees.
- Nine-month stock-based compensation was $8.6m, compared with $0.5m in 2022. Higher investment income partly offset operating losses.
- Comparative loss-per-share figures reflect a major change in weighted-average shares following the November 2022 IPO and the related reverse stock split; per-share comparisons are therefore not directly indicative of operating performance.
Outlook, clinical updates and risks
- Management estimated that September 30 cash, cash equivalents and investments would fund operating expenses and capital requirements into the second half of 2025. The company cautioned that this estimate depends on assumptions and that it will need additional funding; a separate liquidity note says resources are expected to suffice for at least 12 months from issuance of the financial statements.
- The company expects significant, increasing operating losses and expenses as it advances ACR-368, develops ACR-2316 and its broader pipeline, and supports public-company operations. It expects no drug-sales revenue in the foreseeable future.
- In November 2023, after quarter-end, Acrivon reported preliminary imaging-based evidence of clinical activity in a limited number of patients across three tumor types in the ongoing ACR-368 trial. Management described the observations as early; results remain preliminary and require further evaluation. It also reported that drug-related adverse events observed to date were primarily hematological, reversible and manageable.
- ACR-368 received FDA Fast Track designations in May 2023 for monotherapy in OncoSignature-positive platinum-resistant ovarian and endometrial cancer. The OncoSignature test has not been approved, and its successful development and regulatory co-approval are important dependencies for the drug program.
- Key risks include clinical trial efficacy, safety and enrollment; regulatory approval of ACR-368 and its companion diagnostic; reliance on third-party research, manufacturing and diagnostic providers; competition; intellectual-property and Lilly-license obligations; and the need to raise additional capital. Lilly milestone payments may total up to $168.0m, including $5.0m due before an NDA; Akoya milestone payments may total up to $10.3m. No Lilly milestones or royalties had been incurred as of September 30, 2023.
- Management stated that material weaknesses in internal control over financial reporting had not been fully remediated as of September 30, 2023; disclosure controls and procedures were therefore considered ineffective. The filing says the weaknesses had not caused a material misstatement, but could result in one if not addressed.
- The filing notes that Acrivon had access to its SVB funds after the bank’s March 2023 failure, reported no loss, and said it had diversified banking relationships. No material legal proceedings were reported.
Important facts for investors to verify
- Whether the cash runway estimate remains consistent with actual spending, development plans and future financing needs.
- How the ACR-368 trial progresses, including enrollment, mature efficacy and safety data, and the regulatory path for the OncoSignature companion diagnostic.
- Whether and when ACR-2316 advances from preclinical development toward IND-enabling studies and clinical testing.
- Whether internal-control material weaknesses are remediated and controls operate effectively for a sufficient period.
- Potential future dilution or restrictions from financing, equity awards, and contingent Lilly and Akoya milestones.